Regencell Bioscience Holdings RGC
NASDAQ RGC
$6.82 +0.49 (+7.74%)
At close: Oct 2, 2026 · 4:00 PM EDT

Regencell Bioscience Holdings (RGC) Accumulated Expenses (2020 - 2025)

Updated

Regencell Bioscience Holdings' Accumulated Expenses came in at $1.41 million for the quarter ended Dec 31, 2025.

Analysis

Regencell Bioscience Holdings (RGC) Accumulated Expenses (2020 - 2025) Analysis & Trends

As of Jun 30, 2025, Regencell Bioscience Holdings' Accumulated Expenses was $348,354, up 178.0% from the prior year.

  • Accumulated Expenses carries a five-year compound annual growth rate of 29.7% (years ended Jun 2020 to Jun 2025).
  • Going back by year, Accumulated Expenses was $125,328 in the year ended Jun 30, 2024 (-20.7%), $158,081 in the year ended Jun 30, 2023 (+4.6%), $151,127 in the year ended Jun 30, 2022 (-73.6%) and $572,990 in the year ended Jun 30, 2021 (+503.1%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn
10 Regencell Bioscience Holdings 82.37 Mn 75.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.41 Mn
Jun 30, 2025 348,354.00
Jun 30, 2024 125,328.00
Jun 30, 2023 158,081.00
Jun 30, 2022 151,127.00
Jun 30, 2021 572,990.00
Jun 30, 2020 95,000.00
API Access

Regencell Bioscience Holdings Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=RGC&period=max&api_key=YOUR_API_KEY